Lilan Yi

633 total citations
16 papers, 371 citations indexed

About

Lilan Yi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lilan Yi has authored 16 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lilan Yi's work include Epigenetics and DNA Methylation (4 papers), Lung Cancer Research Studies (4 papers) and RNA modifications and cancer (4 papers). Lilan Yi is often cited by papers focused on Epigenetics and DNA Methylation (4 papers), Lung Cancer Research Studies (4 papers) and RNA modifications and cancer (4 papers). Lilan Yi collaborates with scholars based in China. Lilan Yi's co-authors include Xiaofang Zou, Guowu Wu, Longhua Guo, Ping Huang, Peng Luo, Jian Zhang, Junsheng Fan, Hongman Zhang, Jie Shen and Ping Huang and has published in prestigious journals such as International Journal of Cancer, Journal of Cellular Biochemistry and Theranostics.

In The Last Decade

Lilan Yi

13 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lilan Yi China 9 202 136 129 123 25 16 371
Ziming Gao China 14 177 0.9× 78 0.6× 64 0.5× 101 0.8× 36 1.4× 29 337
Xingsheng Qiu China 10 306 1.5× 88 0.6× 92 0.7× 256 2.1× 49 2.0× 21 456
Huangang Jiang China 10 172 0.9× 51 0.4× 108 0.8× 115 0.9× 20 0.8× 16 334
Karin Welén Sweden 8 118 0.6× 142 1.0× 75 0.6× 69 0.6× 9 0.4× 12 278
Tomoko Nukui United States 10 163 0.8× 95 0.7× 110 0.9× 71 0.6× 23 0.9× 17 349
Ana Elisa Lohmann Canada 11 167 0.8× 57 0.4× 240 1.9× 92 0.7× 39 1.6× 27 397
Yifei Ma China 11 126 0.6× 38 0.3× 87 0.7× 104 0.8× 17 0.7× 33 277
Netanya Pollock United States 8 140 0.7× 58 0.4× 158 1.2× 77 0.6× 15 0.6× 11 322
Hangchuan Shi United States 12 299 1.5× 118 0.9× 54 0.4× 213 1.7× 56 2.2× 24 477
Tamara Sequeiros Spain 7 207 1.0× 93 0.7× 31 0.2× 138 1.1× 18 0.7× 8 312

Countries citing papers authored by Lilan Yi

Since Specialization
Citations

This map shows the geographic impact of Lilan Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lilan Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lilan Yi more than expected).

Fields of papers citing papers by Lilan Yi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lilan Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lilan Yi. The network helps show where Lilan Yi may publish in the future.

Co-authorship network of co-authors of Lilan Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Lilan Yi. A scholar is included among the top collaborators of Lilan Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lilan Yi. Lilan Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
3.
Yi, Lilan, Ping Huang, Guowu Wu, et al.. (2022). Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma. Frontiers in Oncology. 12. 794293–794293.
4.
Wu, Guowu, Longhua Guo, Tanxiao Huang, et al.. (2022). The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients. Journal of Cancer Research and Clinical Oncology. 149(3). 1019–1028. 5 indexed citations
5.
Song, Wei, et al.. (2021). Impact of Home Parenting Environment on Cognitive and Psychomotor Development in Children Under 5 Years Old: A Meta-Analysis. Frontiers in Pediatrics. 9. 658094–658094. 22 indexed citations
6.
Guo, Longhua, et al.. (2021). Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report. OncoTargets and Therapy. Volume 14. 1989–1995.
7.
Wu, Guowu, et al.. (2020). Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis. Medical Science Monitor. 26. e920432–e920432. 13 indexed citations
8.
Zhang, Wei, Lilan Yi, Jie Shen, et al.. (2020). Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis. Journal of Cancer. 11(7). 1816–1827. 7 indexed citations
9.
Yi, Lilan, et al.. (2020). Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer. Pharmacological Research. 161. 105144–105144. 36 indexed citations
10.
Yi, Lilan, Guowu Wu, Longhua Guo, Xiaofang Zou, & Ping Huang. (2020). Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma. Molecular Therapy — Nucleic Acids. 21. 299–314. 154 indexed citations
11.
Qiu, Zhengang, Weiliang Zhu, Hui Meng, et al.. (2019). CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics. 9(16). 4717–4729. 34 indexed citations
12.
Yi, Lilan, et al.. (2019). Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis. International Journal of Cancer. 145(1). 284–294. 54 indexed citations
13.
Yi, Lilan, Peng Luo, & Jian Zhang. (2019). Identification of aberrantly methylated differentially expressed genes in breast cancer by integrated bioinformatics analysis. Journal of Cellular Biochemistry. 120(9). 16229–16243. 5 indexed citations
14.
Yi, Lilan, Hongman Zhang, Jingwen Zou, Peng Luo, & Jian Zhang. (2018). Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis. Gynecologic Oncology. 149(3). 612–619. 13 indexed citations
15.
Yi, Lilan, Wei Zhang, Hongman Zhang, et al.. (2018). Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer. Drug Design Development and Therapy. Volume 12. 2455–2466. 17 indexed citations
16.
Zhang, Hongman, Jie Shen, Lilan Yi, et al.. (2018). Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis. Journal of Cancer. 9(23). 4556–4567. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ziming Gao Breakdown of academic impact, for papers by Xingsheng Qiu Breakdown of academic impact, for papers by Huangang Jiang Breakdown of academic impact, for papers by Karin Welén Breakdown of academic impact, for papers by Tomoko Nukui Breakdown of academic impact, for papers by Ana Elisa Lohmann Breakdown of academic impact, for papers by Yifei Ma Breakdown of academic impact, for papers by Netanya Pollock Breakdown of academic impact, for papers by Hangchuan Shi Breakdown of academic impact, for papers by Tamara Sequeiros
Rankless by CCL
2026